Gray Zone Lymphoma: Better Treated Like Hodgkin Lymphoma or Mediastinal Large
B-Cell Lymphoma?
ROBUST: lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large
B-cell lymphoma.
(22,24) Finally, false-positive results can occur when a
B-cell population emerges as a dominant clone in RLH.
A retrospective analysis was performed on 106 patients who were diagnosed with CD20-positive
B-cell non-Hodgkin's lymphoma according to the World Health Organization classification for pathological diagnosis, between January 2010 and April 2017; these patients were administered rituximab-containing chemotherapy, and they completed the follow-up (19).
B-cell epitope prediction aims to facilitate
B-cell epitope identification with the practical purpose of replacing the antigen for antibody production or for carrying structurefunction studies.
Kymriah became the first CAR-T cell therapy to receive regulatory approval when it was approved by the FDA in August 2017 for the treatment of patients up to 25 years of age with
B-cell precursor ALL that is refractory or in second or later relapse.
Immunohistochemically, IVLBCL is positive for
B-cell markers with variable aberrant expression of CD5.
Secondary central nervous system (CNS) involvement in patients with diffuse large
B-cell lymphoma: a therapeutic dilemma.
Results: We found that miR-155 expression levels differentiate lymphoma entities from normal subjects (p [less than or equal to] 0.001) and its expression fold changes distinguish
B-cell lymphoma subtypes from each other's (p<0.05).
Keywords: Chronic lymphocytic leukemia, familial form, monoclonal
B-cell lymphocytosis
It remains controversial about the role of
B-cell subsets in obesity and T2D.
Treatment of
B-cell NHL typically relies upon multiagent cytotoxic chemotherapy (e.g., cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP]), tailored to the specific subtype of NHL and certain patient characteristics.